A phase I trial of temozolomide and lomustine in newly diagnosed high-grade gliomas of childhood
Open Access
- 1 August 2008
- journal article
- research article
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 10 (4) , 569-576
Abstract
A phase I trial was conducted to determine the maximum tolerated dose (MTD) of temozolomide given in combination with lomustine in newly diagnosed pediatric patients with high-grade gliomas. Response was assessed following two courses of therapy at the MTD. Temozolomide was administered to cohorts of patients at doses of 100, 125, 160, or 200 mg/m2 on days 1-5, along with 90 mg/m2 lomustine on day 1. Two courses of lomustine/temozolomide were given prior to radiation therapy (RT) and up to six courses were administered afterward. Thirty-two patients were enrolled. Dose-limiting myelosuppression was seen in two of three patients enrolled at the 200 mg/m2 dose level. One of 14 patients in the expanded MTD cohort (160 mg/m2) experienced dose-limiting thrombocytopenia. After two courses at the MTD, one patient with a 5-mm enhancing nodule postoperatively had a complete response, one patient with a large residual temporal lobe glioblastoma had a partial response, and eight patients had stable disease. Several patients developed transient radiographic worsening after completing RT. Median 1- and 2-year overall survivals at the MTD were 60% ± 13% and 40% ± 13% with a median of 17.6 months. Thirteen of 20 patients (65%) who underwent MRI scans within 6 months prior to death developed metastatic disease. In conclusion, when administered with 90 mg/m2 lomustine on day 1, the MTD of temozolomide is 160 mg/m2/day × 5. Radiographic changes following RT make determination of early tumor progression difficult. Metastatic disease is common prior to death.Keywords
This publication has 30 references indexed in Scilit:
- Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumorsCancer, 2007
- The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiformeNeuro-Oncology, 2007
- O6-Methylguanine-DNA Methyltransferase Expression Strongly Correlates With Outcome in Childhood Malignant Gliomas: Results From the CCG-945 CohortJournal of Clinical Oncology, 2006
- Cerebral radiation necrosis: Incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2006
- Phase II study of high‐dose chemotherapy before radiation in children with newly diagnosed high‐grade astrocytomaCancer, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid NeoplasmsClinical Cancer Research, 2004
- Preradiation chemotherapy for pediatric patients with high‐grade gliomaCancer, 2001
- Supratentorial malignant gliomas in childhood: A review of fifty casesAnnals of Neurology, 1987
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958